Member Info for pjmcgra

What is the price 0.00301 or 0.301, big difference,I'm slightly confused,
Can someone shed some light
PJ

Frazier, give him 3 cheers

PJ

Comforting words from The latest RNS,with Richard Hullihen,sounding more confident after speaking to the FDA
This is a buy for me,
Excerpts from latest RNS. 31/3/2022

The NDA filing follows the Company's receipt of a Complete Response Letter ("CRL") from the FDA on 6 October 2021. Following detailed discussion in the Type A meeting with the FDA, these issues have now been addressed by Polarean in the resubmission.
It is currently expected that the FDA review period will take six months. The Company is making full use of this time with regards to commercialisation and launch preparation and will further update the market once material information is received.
Richard Hullihen, CEO of Polarean, said: "We have resubmitted the NDA for our 129Xenon drug-device combination product, following extensive discussions with the FDA regarding the issues that were raised in the CRL. The entire Polarean team has worked diligently to ensure that all the points raised in the CRL were comprehensively addressed".
"We look forward to completing the FDA review and approval processes necessary to bring our unique technology to market addressing the significant unmet need for our non-invasive, quantitative and cost-effective functional lung imaging."

BL747, Thanks for that little snippet ,every bit helps

Appreciate your info ,recommended

Hi Ghia, nice to hear from you,
Question, do you think Richard Marsden is harshly treated on this board,
Personally, he is honest and candid when it comes to diplomacy and imo deserves a little respect .
I am LTH and heavily in the red ,but along with a good few I still think this has potential although the S P doesn't show it.
GLAH
PJ

Thanks Tommy for that ,
didn't know it was that expansive and quite an influential fraternity ,if this happens, synairgen may control the trial themselves perhaps.
PJ

Thanks Tommy, forgive my ignorance who is the platform that will pay for the trials.I
OK

Manifesto
Totally agree, but can you state how the platform trials are costed, with only £48 million market cap , is this enough or will it be RM asking for funding and more shares required.
PJ

Andy , Sorry OTT , now filtered

Thanks Gordon.

I like the discussion about Cambay, long may it continue,
that aside ,is there any further progress on the Carbon Capture licensing update,another lucrative project in the making Imo.Last heard on the 28th Feb
GLAH

Treatments
Asthma can be managed with medications. Medications vary depending on the severity of symptoms. The medications are administered through inhalers or nebulizers. The medication through tablets helps manage the condition.
Medication
Inhaled short-acting beta-2-agonists: Quick relief inhalators reduces the symptoms like shortness of breath. Usually prescribed for quick relief of symptoms.
Albuterol · Terbutaline
Inhaled steroids: Help in reducing the airway inflammation. Usually given for severe symptoms.
Fluticasone · Budesonide
Inhaled long-acting beta-2-agonists: Help in dilation of airways. Usually prescribed for chronic condition.
Formoterol · Salmeterol
Leukotriene-modifying agents: Help in both dilation of airways and reducing inflammation. For managing symptoms.
Zafirlukast · Zileuton
Xanthines: Help in dilation of airways. Usually prescribed if sudden shortness of breath occurs.
Theophylline
Beta-2-agonist tablets: Help in dilation of airways.
Levalbuterol · Metaproterenol
IL-4 antagonist: Reduces inflammation of airways. Usually given in moderate to severe cases.
Reslizumab
Steroid tablets: Help in reducing the airway inflammation. Usually given in severe uncontrolled cases.
Prednisone · Beclomethasone dipropionate
IL-5 antagonist: Reduces inflammation of airways. Usually given in severe uncontrolled cases.
Mepolizumab
IL-5 receptor antagonist: Reduces inflammation of airways. Usually given in severe uncontrolled cases.
Benralizumab
__________________________________
Just an extract from Google,
based on the original study and trials looking for a remedy to figure out Astmathic and COPD, patients already have the list of steroids in them tablet and inhaled . SNG001 was the one being trailed ,then covi d came along, My point is , were there more stronger steroids not known to the synairgen team , as they would have been aware of the named drugs above.
Hopefully Sprinter will reveal all.
GLAH.

Just topped up at £410 ,185k shares,comes.out as a sell and not a buy ,what's going on LSE.

SH, thanks fo d that.

Hi guys what does it mean in terms " A substantial holding change, is it a large investment by an existing broker,is it significant.
I can't see it ,whoever they are talking about,

Sorry guys,
but I was just browsing the 14/2/2022 RNS and seem to dismiss the fact that Polarean have had a research unit order for a Xenon Polariser system from McMaster University in Ontario, Canada.
The newest unit (version 9820) will supplement the University's existing hyperpolarisation 129Xe MRI research programme which is currently using a prior Polarean model (version 9800).
I was surprised when I 're read "the newest version 9820" .
Now if we are following , is this the version Polarean wish to resubmit as an NDA, this after following feedback data.
Or am I wrong , and they will submit the older version type 9800 .It has been 7 months to date, interesting ,
Your thoughts please.
PJ

Not sure if they are buys or sells ,will be interesting on opening tomorrow.
PJ

Sorry, medical , that damn word seach
PJ

I am sadly invested in SNG ,as you well know have had a devastating result in trials,leading the NIH ( body of the FDA )to halt proceedings due to further data required . I believed they have stopped most applications as COVID is not so prevalent now for the time being.
My thought is , this would be a good time to reapply for NDA and FDA approva!.
Your thoughts !
This time they will have the knowledge of a pioneering medieval device

Do we know they are definite buys and not sells , if so what a boost to the week ahead.
Fingers crossed.